BioCentury | Apr 15, 2013
Financial News

AdvanceCOR completes venture financing

...Bayern Kapital; Bio-M; Hightech-Grunderfonds; KfW Note: AdvanceCOR was created to develop the product portfolio of CorImmun GmbH...
...Janssen-Cilag GmbH subsidiary of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) in its acquisition of CorImmun...
BioCentury | Jul 2, 2012
Company News

Corimmun, J&J deal

...Johnson & Johnson's Janssen-Cilag GmbH unit acquired CorImmun for an upfront payment and milestones. CorImmun's COR-1...
...Phase I trial in heart failure. Details were not disclosed (see BioCentury, March 29, 2010). CorImmun GmbH...
BioCentury | Mar 29, 2010
Clinical News

COR-1: Phase I data

...vivo efficacy with almost complete scavenging of pathological ADRB1 autoantibodies at the 2 highest doses. Corimmun GmbH...
Items per page:
1 - 3 of 3
BioCentury | Apr 15, 2013
Financial News

AdvanceCOR completes venture financing

...Bayern Kapital; Bio-M; Hightech-Grunderfonds; KfW Note: AdvanceCOR was created to develop the product portfolio of CorImmun GmbH...
...Janssen-Cilag GmbH subsidiary of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) in its acquisition of CorImmun...
BioCentury | Jul 2, 2012
Company News

Corimmun, J&J deal

...Johnson & Johnson's Janssen-Cilag GmbH unit acquired CorImmun for an upfront payment and milestones. CorImmun's COR-1...
...Phase I trial in heart failure. Details were not disclosed (see BioCentury, March 29, 2010). CorImmun GmbH...
BioCentury | Mar 29, 2010
Clinical News

COR-1: Phase I data

...vivo efficacy with almost complete scavenging of pathological ADRB1 autoantibodies at the 2 highest doses. Corimmun GmbH...
Items per page:
1 - 3 of 3